Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) EBIT Margin (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has 6 years of EBIT Margin data on record, last reported at 5226.32% in Q4 2020.

  • For Q4 2020, EBIT Margin fell 148816.0% year-over-year to 5226.32%; the TTM value through Dec 2020 reached 4708.17%, down 91523.0%, while the annual FY2025 figure was 158.45%, 127598.0% up from the prior year.
  • EBIT Margin reached 5226.32% in Q4 2020 per SNDX's latest filing, roughly flat from 5238.26% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1633.61% in Q4 2017 and bottomed at 5238.26% in Q3 2020.
  • Average EBIT Margin over 5 years is 4195.8%, with a median of 4351.46% recorded in 2017.
  • Peak YoY movement for EBIT Margin: soared 2976918bps in 2016, then plummeted -345402bps in 2018.
  • A 5-year view of EBIT Margin shows it stood at 3652.79% in 2016, then soared by 55bps to 1633.61% in 2017, then tumbled by -211bps to 5087.63% in 2018, then grew by 27bps to 3738.16% in 2019, then tumbled by -40bps to 5226.32% in 2020.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 5226.32% in Q4 2020, 5238.26% in Q3 2020, and 4382.59% in Q2 2020.